Siglecs as Therapeutic Targets in Cancer

Hypersialylation is a common post-translational modification of protein and lipids found on cancer cell surfaces, which participate in cell-cell interactions and in the regulation of immune responses. Sialic acids are a family of nine-carbon α-keto acids found at the outermost ends of glycans attach...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jackwee Lim, Duygu Sari-Ak, Tanaya Bagga
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	Siglec sialic acid cancer immunosuppressive anti-Siglec treatment Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/a5f210a3298541d1833f0dbe28ed2b3c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a5f210a3298541d1833f0dbe28ed2b3c
record_format	dspace
spelling	oai:doaj.org-article:a5f210a3298541d1833f0dbe28ed2b3c2021-11-25T16:47:43ZSiglecs as Therapeutic Targets in Cancer10.3390/biology101111782079-7737https://doaj.org/article/a5f210a3298541d1833f0dbe28ed2b3c2021-11-01T00:00:00Zhttps://www.mdpi.com/2079-7737/10/11/1178https://doaj.org/toc/2079-7737Hypersialylation is a common post-translational modification of protein and lipids found on cancer cell surfaces, which participate in cell-cell interactions and in the regulation of immune responses. Sialic acids are a family of nine-carbon α-keto acids found at the outermost ends of glycans attached to cell surfaces. Given their locations on cell surfaces, tumor cells aberrantly overexpress sialic acids, which are recognized by Siglec receptors found on immune cells to mediate broad immunomodulatory signaling. Enhanced sialylation exposed on cancer cell surfaces is exemplified as “self-associated molecular pattern” (SAMP), which tricks Siglec receptors found on leukocytes to greatly down-regulate immune responsiveness, leading to tumor growth. In this review, we focused on all 15 human Siglecs (including Siglec XII), many of which still remain understudied. We also highlighted strategies that disrupt the course of Siglec-sialic acid interactions, such as antibody-based therapies and sialic acid mimetics leading to tumor cell depletion. Herein, we introduced the central roles of Siglecs in mediating pro-tumor immunity and discussed strategies that target these receptors, which could benefit improved cancer immunotherapy.Jackwee LimDuygu Sari-AkTanaya BaggaMDPI AGarticleSiglecsialic acidcancerimmunosuppressiveanti-SiglectreatmentBiology (General)QH301-705.5ENBiology, Vol 10, Iss 1178, p 1178 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Siglec sialic acid cancer immunosuppressive anti-Siglec treatment Biology (General) QH301-705.5
spellingShingle	Siglec sialic acid cancer immunosuppressive anti-Siglec treatment Biology (General) QH301-705.5 Jackwee Lim Duygu Sari-Ak Tanaya Bagga Siglecs as Therapeutic Targets in Cancer
description	Hypersialylation is a common post-translational modification of protein and lipids found on cancer cell surfaces, which participate in cell-cell interactions and in the regulation of immune responses. Sialic acids are a family of nine-carbon α-keto acids found at the outermost ends of glycans attached to cell surfaces. Given their locations on cell surfaces, tumor cells aberrantly overexpress sialic acids, which are recognized by Siglec receptors found on immune cells to mediate broad immunomodulatory signaling. Enhanced sialylation exposed on cancer cell surfaces is exemplified as “self-associated molecular pattern” (SAMP), which tricks Siglec receptors found on leukocytes to greatly down-regulate immune responsiveness, leading to tumor growth. In this review, we focused on all 15 human Siglecs (including Siglec XII), many of which still remain understudied. We also highlighted strategies that disrupt the course of Siglec-sialic acid interactions, such as antibody-based therapies and sialic acid mimetics leading to tumor cell depletion. Herein, we introduced the central roles of Siglecs in mediating pro-tumor immunity and discussed strategies that target these receptors, which could benefit improved cancer immunotherapy.
format	article
author	Jackwee Lim Duygu Sari-Ak Tanaya Bagga
author_facet	Jackwee Lim Duygu Sari-Ak Tanaya Bagga
author_sort	Jackwee Lim
title	Siglecs as Therapeutic Targets in Cancer
title_short	Siglecs as Therapeutic Targets in Cancer
title_full	Siglecs as Therapeutic Targets in Cancer
title_fullStr	Siglecs as Therapeutic Targets in Cancer
title_full_unstemmed	Siglecs as Therapeutic Targets in Cancer
title_sort	siglecs as therapeutic targets in cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a5f210a3298541d1833f0dbe28ed2b3c
work_keys_str_mv	AT jackweelim siglecsastherapeutictargetsincancer AT duygusariak siglecsastherapeutictargetsincancer AT tanayabagga siglecsastherapeutictargetsincancer
_version_	1718412974802075648

Siglecs as Therapeutic Targets in Cancer

Ejemplares similares